Interim recommendations for heterologous COVID-19 vaccine schedules
Interim guidance
16 December 2021
| COVID-19: Vaccines
Overview
This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
For translations in other WHO languages click here.